Discordant 18F-FES PET and ER immunohistochemistry in ER-positive bone metastasis: a potential imaging pitfall
Anne-Claire Dupont, Lucas Gaouaou, Anne-Marie Bergemer-Fouquet, Marie-Agnès By, Maria-Joao Santiago-Ribeiro · 2026
Read Discordant 18F-FES PET and ER immunohistochemistry in ER-positive bone metastasis: a potential imaging pitfall by Anne-Claire Dupont, Lucas Gaouaou, Anne-Marie Bergemer-Fouquet, Marie-Agnès By, Maria-Joao Santiago-Ribeiro (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13633171.txt.
Description
Anne-Claire Dupont and four colleagues published this 2026 case report on a cancer scan that disagreed with a tissue test. A forty-eight-year-old woman had been treated for hormone-sensitive breast cancer. Four years later, pain led to a suspicious spot on her breastbone. One scan type, which tracks sugar use, lit up strongly there. A second scan, designed to light up where estrogen receptors are active, showed nothing in the same spot.
A biopsy settled the question: the spot was metastatic cancer whose cells still carried estrogen receptors strongly. The second tracer reports whether receptors are free to bind, not whether they exist. Leftover drug effects, changed receptors, or uneven tumor biology can all hide uptake. The authors warn that a blank scan must never be read as missing receptors, since that mistake could steer patients away from hormone therapy that might help.
Catalog record
| CREATOR | Anne-Claire Dupont, Lucas Gaouaou, Anne-Marie Bergemer-Fouquet, Marie-Agnès By, Maria-Joao Santiago-Ribeiro |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3147 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |